Prognostic value of high c-Met expression in patients with poor prognosis pancreatic adenocarcinoma (PAC) following surgical resection: comparison of three c-Met scoring methods and exploration of underlying mechanisms of c-Met overexpression

Pancreatology ◽  
2015 ◽  
Vol 15 (3) ◽  
pp. S25-S26
Author(s):  
Cindy Neuzillet ◽  
Annemilaï Tijeras-Raballand ◽  
Jérôme Raffenne ◽  
Armand D.E. Gramont ◽  
Pierre Bedossa ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Surgical Resection ◽  
Poor Prognosis ◽  
Prognostic Value ◽  
Scoring Methods ◽  
Underlying Mechanisms ◽  
Patients With Poor Prognosis

scholarly journals Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection

2020 ◽  
Vol 9 (8) ◽  
pp. 2440
Author(s):  
Natalia Gablo ◽  
Karolina Trachtova ◽  
Vladimir Prochazka ◽  
Jan Hlavsa ◽  
Tomas Grolich ◽  
...  
Keyword(s):  
Blood Plasma ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Surgical Resection ◽  
Poor Prognosis ◽  
Ductal Adenocarcinoma ◽  
Small Rna Sequencing ◽  
High Morbidity ◽  
Plasma Samples ◽  
Circulating Micrornas ◽  
Patients With Poor Prognosis

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and aggressive cancers with a less than 6% five-year survival rate. Circulating microRNAs (miRNAs) are emerging as a useful tool for non-invasive diagnosis and prognosis estimation in the various cancer types, including PDAC. Our study aimed to evaluate whether miRNAs in the pre-operative blood plasma specimen have the potential to predict the prognosis of PDAC patients. In total, 112 PDAC patients planned for surgical resection were enrolled in our prospective study. To identify prognostic miRNAs, we used small RNA sequencing in 24 plasma samples of PDAC patients with poor prognosis (overall survival (OS) < 16 months) and 24 plasma samples of PDAC patients with a good prognosis (OS > 20 months). qPCR validation of selected miRNA candidates was performed in the independent cohort of PDAC patients (n = 64). In the discovery phase of the study, we identified 44 miRNAs with significantly different levels in the plasma samples of the group of good and poor prognosis patients. Among these miRNAs, 23 showed lower levels, and 21 showed higher levels in plasma specimens from PDAC patients with poor prognosis. Eleven miRNAs were selected for the validation, but only miR-99a-5p and miR-365a-3p were confirmed to have significantly lower levels and miR-200c-3p higher levels in plasma samples of poor prognosis cases. Using the combination of these 3-miRNA levels, we were able to identify the patients with poor prognosis with sensitivity 85% and specificity 80% (Area Under the Curve = 0.890). Overall, 3-miRNA prognostic score associated with OS was identified in the pre-operative blood plasma samples of PDAC patients undergoing surgical resection. Following further independent validations, the detection of these miRNA may enable identification of PDAC patients who have no survival benefit from the surgical treatment, which is associated with the high morbidity rates.

scholarly journals Cardiac biomarkers alterations in patients with SARS-CoV-2 infection

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Eleousa Oikonomou ◽  
Themistoklis Paraskevas ◽  
Dimitrios Velissaris
Keyword(s):  
Poor Prognosis ◽  
Prognostic Value ◽  
Troponin I ◽  
High Sensitivity ◽  
Cardiac Biomarkers ◽  
Direct Damage ◽  
Poor Outcomes ◽  
Novel Coronavirus ◽  
Lower Limits ◽  
Patients With Poor Prognosis

Abstract Reliable biomarkers are necessary for the risk stratification of patients infected with SARS-CoV-2. This novel coronavirus is now established to affect several organs in addition to the lungs, most prominently the heart. This is achieved through direct damage to the myocardium and indirect immune-associated effects during the cytokine storm. We performed a literature review aiming to identify the prognostic value of alterations of cardiac biomarkers in SARS-CoV-2 infection. Cardiac biomarkers are significantly elevated in patients with severe COVID-19 and are independent predictors of mortality. High-sensitivity troponin I and T are correlated with multiple inflammatory indexes and poor outcomes. Although cut-off values have been established for most of cardiac biomarkers, lower limits for troponins may have better prognostic values and longitudinal monitoring of cardiac biomarkers can help the clinician assess the patient’s course. Additional measurements of NT-proBNP, can detect the subgroup of patients with poor prognosis.

scholarly journals Racial Disparities in Surgical Resection and Survival among Elderly Patients with Poor Prognosis Cancer

2013 ◽  
Vol 216 (2) ◽  
pp. 312-319 ◽  
Author(s):  
Sha'Shonda L. Revels ◽  
Mousumi Banerjee ◽  
Huiying Yin ◽  
Christopher J. Sonnenday ◽  
John D. Birkmeyer
Keyword(s):  
Elderly Patients ◽  
Racial Disparities ◽  
Surgical Resection ◽  
Poor Prognosis ◽  
Patients With Poor Prognosis

Racial disparities in surgical resection and survival among patients with poor prognosis cancer

2012 ◽  
Vol 215 (3) ◽  
pp. S106
Author(s):  
Sha'Shonda L. Revels ◽  
Mousumi Banerjee ◽  
Huiying Yin ◽  
Christopher J. Sonnenday ◽  
John D. Birkmeyer
Keyword(s):  
Racial Disparities ◽  
Surgical Resection ◽  
Poor Prognosis ◽  
Patients With Poor Prognosis

scholarly journals Long-term survival in a cat with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate

2020 ◽  
Vol 6 (1) ◽  
pp. 205511692092491
Author(s):  
Johanna E Todd ◽  
Sandra M Nguyen
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Surgical Resection ◽  
Side Effect ◽  
Poor Prognosis ◽  
Term Survival ◽  
Free Interval ◽  
Case Summary ◽  
First Case ◽  
Uncommon Neoplasm

Case summary Primary pancreatic adenocarcinoma is an uncommon neoplasm seen in cats and often has a poor prognosis. We report a case of an 8-year-old male neutered domestic shorthair cat weighing 5.8 kg diagnosed with pancreatic adenocarcinoma treated with surgical resection and toceranib phosphate, which had a progression-free interval of 1148 days and survived for more than 1436 days. The treatment was well tolerated; however, the cat developed generalised coat hypopigmentation. Relevance and novel information To our knowledge, the cat in our report has the longest progression-free interval and survival time post-surgical resection of pancreatic carcinoma treated with toceranib. Hypopigmentation as a side effect of toceranib has been reported in dogs, but this is the first case reported in cats.

scholarly journals Impact of Surgical Resection and Reasons for Poor Prognosis of Pelvic Osteosarcoma Based on the Bone Tumor Registry in Japan

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3320
Author(s):  
Satoshi Takenaka ◽  
Hironari Tamiya ◽  
Toru Wakamatsu ◽  
Sho Nakai ◽  
Yoshinori Imura ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Propensity Score ◽  
Surgical Resection ◽  
Bone Tumor ◽  
Poor Prognosis ◽  
Propensity Score Analysis ◽  
The Elderly ◽  
Tumor Stage ◽  
Tumor Registry ◽  
Score Analysis

Pelvic osteosarcoma has a poor prognosis compared to osteosarcomas in other locations, and the reasons for this remain unknown. Surgical resection of pelvic osteosarcoma is technically demanding and often results in dysfunction and complications. In this study, we investigated the reasons underlying the poor prognosis of pelvic osteosarcoma by comparing it to femoral osteosarcoma using data from the Bone Tumor Registry in Japan. We used propensity score analysis to determine whether surgical resection of pelvic osteosarcoma improved its prognosis. We demonstrated that pelvic osteosarcoma had a poor prognosis because it occurred more often in the elderly, often had larger tumor size, and had metastasis at presentation more often in comparison to femoral osteosarcoma. These three factors were also associated with the non-surgical treatment of pelvic osteosarcoma, which also led to a poor outcome. The overall survival rate was only comparable in pelvic osteosarcoma and femoral osteosarcoma in cases treated with surgical resection. Propensity score analysis revealed that surgical treatment improved the prognosis of pelvic osteosarcoma. As such, we propose that surgical resection should be considered based on tumor stage and patient age in order to improve the prognosis of pelvic osteosarcoma.

Sign in / Sign up

Export Citation Format

Share Document